Bifeprunox Mesylate (CAS 350992-13-1)
QUICK LINKS
Bifeprunox Mesylate is a compound that functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors. It acts by binding to these receptors and modulating their activity, leading to a mixed agonist-antagonist effect. Bifeprunox Mesylate′s mechanism of action involves influencing the transmission of dopamine and serotonin in the brain, which can impact various physiological processes. By interacting with these receptors, Bifeprunox Mesylate can potentially affect neurotransmitter release, signal transduction, and neuronal firing patterns. Its functional role in experimental applications involves serving to investigate the complex interplay between dopamine and serotonin signaling pathways. Bifeprunox Mesylate′s mechanism of action at the molecular and cellular level provides insights into the regulation of neurotransmission and its potential implications for various physiological functions.
Bifeprunox Mesylate (CAS 350992-13-1) References
- Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. | Kleven, MS., et al. 2005. Neuropharmacology. 49: 135-43. PMID: 15996562
- Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. | Bardin, L., et al. 2006. Neuropsychopharmacology. 31: 1869-79. PMID: 16237379
- Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. | Auclair, AL., et al. 2006. Neuropsychopharmacology. 31: 1900-9. PMID: 16421514
- Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. | Bardin, L., et al. 2007. Behav Pharmacol. 18: 103-18. PMID: 17351418
- Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. | Auclair, AL., et al. 2007. Psychopharmacology (Berl). 193: 45-54. PMID: 17393144
- Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. | Auclair, AL., et al. 2009. Behav Brain Res. 203: 288-95. PMID: 19464324
- Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. | Natesan, S., et al. 2011. Int J Neuropsychopharmacol. 14: 1165-78. PMID: 21087552
- Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. | Zhang, H., et al. 2011. J Med Chem. 54: 4324-38. PMID: 21591752
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bifeprunox Mesylate, 10 mg | sc-207356 | 10 mg | $337.00 |